Ginsenoside Rb1 increases insulin sensitivity through suppressing 11β-hydroxysteroid dehydrogenase type I

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Ginsenoside Rb1 (GRb1), a key ginseng component, shows potential in managing hyperglycemia.
• The precise molecular mechanisms underlying GRb1's anti-diabetic effects, particularly concerning insulin resistance, remain largely undetermined.

Purpose of the Study:

• To investigate the molecular mechanisms by which GRb1 improves insulin sensitivity in a mouse model of type 2 diabetes (T2D).
• To elucidate the role of 11β-Hydroxysteroid dehydrogenase type I (11β-HSD1) in mediating GRb1's anti-diabetic actions.

Main Methods:

• Induction of T2D in mice using a 4-week high-fat diet (HFD).
• Administration of GRb1 to HFD-induced diabetic mice.
• Analysis of fasting blood glucose, glucose tolerance, and insulin sensitivity.
• Assessment of 11β-HSD1 levels in liver and adipose tissue.
• Evaluation of GRb1's effects in mice with overexpressed 11β-HSD1.

Main Results:

• HFD significantly increased fasting blood glucose, impaired glucose tolerance, and reduced insulin sensitivity.
• GRb1 administration effectively ameliorated these HFD-induced metabolic disturbances.
• GRb1 treatment led to reduced levels of 11β-HSD1 in the liver and adipose tissue.
• Overexpression of 11β-HSD1 negated the beneficial effects of GRb1 on glucose metabolism and insulin sensitivity.

Conclusions:

• GRb1 demonstrates significant potential in ameliorating hyperglycemia and insulin resistance associated with T2D.
• The anti-diabetic effects of GRb1 appear to be mediated, at least in part, by the suppression of hepatic and adipose 11β-HSD1.
• Targeting 11β-HSD1 may represent a viable therapeutic strategy for T2D, with GRb1 as a potential therapeutic agent.